In a meta-analysis, Abaloparatide showed remarkable benefits of bone mineral density (BMD) alteration in all comparisons with placebo and improved outcomes of BMD on femoral neck and total hip than Teriparatide in 24 weeks in women with postmenopausal osteoporosis. Researchers compared Teriparatide with Abaloparatide to determine which is more effective and safe for increasing BMD.  Databases like Cochrane, Medline, Embase, Web of Science, and Clinicaltrial.gov were searched. Information was used from randomised controlled trials (RCTs) as well as post hoc analyses of RCTs.

BMD alteration from baseline and the likelihood of adverse events were the outcomes. Using  Grading of Recommendations, Assessment, Development and Evaluation (GRADE) tool, the quality of the results was assessed. This analysis comprised four trials with a total of 16 subgroups. The Abaloparatide group considerably outperformed Teriparatide in every metric throughout the course of 24 weeks, with the exception of lumbar spine. High GRADE quality was noted in 2 subgroups of Abaloparatide versus Teriparatide (total hip: WMD = 1.46 [0.59, 2.32]; femoral neck: weighted mean difference (WMD) = 1.58 [0.52, 2.63]).

The fracture data was found to be insufficient.  No profound difference was noted in severe adverse events or mortality in either of the group. The occurrence of hypercalcemia in the Abaloparatide group reduced by 51% when compared to  Teriparatide group. In comparison with placebo, Abaloparatide illustrated greater risks of palpitations and nausea.

For postmenopausal females suffering from osteoporosis, Abaloparatide outperformed Teriparatide and the placebo in terms of improving BMD. Additionally, the risk of adverse events was somewhat reduced with Aboloparide compared with Teriparatide. Thus, Abaloparatide is a viable substitute for the management of postmenopausal osteoporosis.